Contacts
Ross McNaughton

Ross McNaughton

Partner

Read More
Richard Faichney

Richard Faichney

Senior associate

Read More
Contacts
Ross McNaughton

Ross McNaughton

Partner

Read More
Richard Faichney

Richard Faichney

Senior associate

Read More

10 March 2021

Advising leading-edge life sciences companies on transformational roll-up and $114m crossover financing

We have advised Oppilan Pharma Limited and Zomagen Biosciences Limited on their roll-up and sale into Ventyx Biosciences, Inc. and concurrent $114m crossover financing led by venBio Partners. 

Ventyx, Oppilan and Zomagen were established as asset-centric companies with immunology compounds, each linked to founder, Raju Mohan, and backed by New Science Ventures. The transaction has brought together the three cutting-edge life sciences companies to create a clinical-stage biotechnology company advancing a pipeline of immune modulators to treat inflammatory diseases and autoimmune disorders. The combined venture has attracted a top tier international investor base, including Third Point, RTW Investments, Janus Henderson Investors, Wellington Management and Orbimed. 

Commenting on the deal, Corporate Technology Partner Ross McNaughton, said: "The deal comes hot on the heels of the recent Centessa roll-up and $250m financing that we acted on last month and underlines our expertise in the life sciences market. I have been working with Oppilan and Zomagen since their UK inceptions in 2015 and 2019 and throughout their various funding rounds, we are excited to see this round come together and wish them very well in the next phase of their development."

The team was led by Corporate Technology Partner Ross McNaughton with support from Associate Richard Faichney.  

We advised as UK legal counsel on the transaction in collaboration with Wilson Sonsini Goodrich & Rosati (WSGR), who served as US counsel.

This is the second high-profile roll-up and crossover financing within a month that the firm has acted on, following the $250 million raise by Centessa Therapeutics.

This deal represents another sizable corporate transaction for our Life Sciences & Healthcare team, which continues to operate at the top of the market. The team works with many of the industry's cutting-edge pharmaceutical, biotechnology, and medical device companies, from leading multinationals to earlier stage enterprises ready to up-scale their business. We guide ambitious global clients within these dynamic and innovative industries through the maze of connected legal, commercial, and regulatory challenges.

Call To Action Arrow Image

Latest insights in your inbox

Subscribe to newsletters on topics relevant to you.

Subscribe
Subscribe

Related Insights

Genetically modified wheat growing in a petri dish
Life sciences & healthcare

Acting on transformational roll-up and $250 million crossover financing of cutting-edge UK and European biotech companies

16 February 2021

by Ross McNaughton and Colin McCall

Click here to find out more
robot-thinking
Technology, media & communications

Advising on the sale of Cambridge AI company SciBite to Elsevier

21 August 2020

by multiple authors

Click here to find out more